Abstract library

599 results for "High doses".
#588 CORRELATION OF TUMOR ABSORBED DOSES OF 177LU-DOTA-TATE TREATMENT WITH PRE-THERAPEUTIC GA68 DOTA-TATE PET/CT UPTAKE IN NEUROENDOCRINE TUMORS
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 aroused great interest. Estimation of actual radiation doses to tumors may help therapy planning.
Conference:
Category: Clinical
Presenting Author: Dr. Demirci Emre
Authors: demirci E, kabasakal L, toklu T, ocak M, ...
#2087 Prospective, Multi-Center, Open Label, Phase Study II of APOC, a New Controlled Release 15mg Octreotide Acetate, for the Treatment of Advanced NETs
Introduction: Somatostatin analogues (SSAs) are the cornerstone of systemic therapy of advanced NETs. The efficacy controlling hormone release and tumor growth together with the favorable toxicity profile have positioned SSAs as upfront therapy. Despite of second-line therapies including targeted agents, chemotherapy and radiolabeled peptides have demonstrated activity controlling tumor growth, the less favorable toxicity profiles become a usual discussion with patients (pts) to preserve the quality of life (QoL). Additionally, from concordant flow of evidences clinical benefits could be obtained with higher SSAs circulating levels but remain unreachable with current products. APOC is a new controlled release ready-to-use convenient therapeutic, designed to cover specifically these clinical unmet needs.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Jaume Capdevila
#1534 Personalized 177Lu-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) Allows a Safe and Significant Increase of Radiation Dose to Neuroendocrine Tumors (NETs)
Introduction: 177Lu-octreotate PRRT is commonly administered at fixed/empiric activity per cycle, which results in highly variable radiation doses to critical organs and undertreatment of the majority of patients.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Michela Del Prete
#880 Novel Succinate Dehydrogenase Subunit B Intronic Mutation in an Australian Kindred with Variable Clinical and Imaging Phenotype Necessitating Different Treatment Modalities Including 131-I MIBG and 177-Lutetium DOTATATE
Introduction: SDH B mutation has variable functional imaging phenotype challenging in terms of diagnosis, treatment modalities and follow-up.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Kevin Lee
Authors: Lee K, Conway L, Burge M, Wyld D, ...
Keywords: SDHB, Paraganglioma
#1538 Safety of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial
Introduction: Dose escalation (or interval reduction) of somatostatin analogs (SSAs) is a rather common strategy for patients (pts) with progressive metastatic neuroendocrine tumors (NETs). However, to date, no systematic prospective studies have been carried out to evaluate safety and efficacy of this treatment schedule in NETs.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD, PhD Manuela Albertelli
#64 Sustained response to anti IGFR-1R monoclonal antibody combined with docetaxel in a patient with metastatic adrenocortical carcinoma
Introduction: Adrenocortical carcinoma (ACC) is a rare neoplasm with poor prognosis. Treatment results in advanced disease are disappointing and median survival is less than 12 months. There is no standard chemotherapy, even though mitotane and cisplatin-based regimens are frequently used with limited efficacy. In vitro data suggest that overexpressed insulin growth factor-2 (IGF-2) acting via the IGF-1 receptor (IGF-1R) is relevant for ACC and that the IGF-1R and 2R pathway is a promising target.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Sara De Dosso
#131 Efficacy and safety results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR
Introduction: Pasireotide, a multi-receptor targeted somatostatin analogue, has 30-, 5- and 39-fold greater affinity for sst1,3 and sst5 receptors, respectively, and a slightly lower affinity for sst2, than octreotide. Because of this multi-receptor binding profile, pasireotide may be effective in controlling symptoms of carcinoid syndrome in patients with gastroenteropancreatic neuroendocrine tumors (NETs) who are no longer responsive to currently available somatostatin analogues.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Larry K Kvols
#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors
Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#1057 Localisation of Insulinoma and Beta-Cells: Comparison of Glucagon-Like Peptide-1 Receptor (GLP1-R) SPECT/CT, PET/CT and MRI. Preliminary Results of a Prospective Clinical Study.
Introduction: SPECT/CT imaging with GLP1-R specific radiotracers like 111In-DOTA-exendin-4 have already proved to be a useful tool for the preoperative localisation of insulinomas. PET/CT has several advantages over SPECT/CT: lower radiation exposure, less time consumption and higher spatial resolution.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Christof Rottenburger
Authors: Rottenburger C, Antwi K, Heye T, Fani M, ...
#1135 The Role of External Beam Radiotherapy in the Management of Advanced Neuroendocrine Tumors
Introduction: Palliative external beam radiotherapy (EBRT) is routinely used to control symptoms and disease progression in metastatic malignancies, but there is limited data in metastatic neuroendocrine tumours (NET).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Others
Presenting Author: Dr Mehmet Yalchin
Keywords: EBRT, NET